ALIVUS

Alivus Life Sciences’ strong quarterly results reported for the period ending December 2025. The company posted its highest-ever quarterly net sales of ₹672.89 crores, alongside a record PBDIT of ₹231.28 crores. The operating profit margin relative to net sales also reached a peak of 34.37%, signalling efficient cost management and robust profitability. These figures highlight the company’s operational strength and ability to generate healthy earnings growth. Management efficiency is another key factor supporting investor optimism. Alivus boasts a high return on equity (ROE) of 18.73%, reflecting effective utilisation of shareholder capital. The company is also net-debt free, which reduces financial risk and enhances balance sheet stability. Despite trading at a premium price-to-book value of 4.5, the valuation appears justified given the company’s strong profitability and growth metrics. Over the past year, while the stock’s price appreciation was relatively modest at 1.92%, the company’s profits have increased by 27.5%. This divergence suggests that earnings growth is outpacing share price gains, potentially indicating undervaluation or room for further price appreciation. The PEG ratio of 0.9 further supports this view, implying that the stock’s price growth is reasonable relative to its earnings growth